Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study
What If the Peptide Shows No Effect in Your Vascular Injury Model
It is important to note that Hydroxocobalamin 20 mg/ml Injection Solution should not be used in patients with known hypersensitivity to hydroxocobalamin or any of the other ingredients in the solution
BPC-157 has been shown in numerous preclinical models to significantly promote the outgrowth of endothelial cells, which are the building blocks of your entire vascular system
Review of publicly searchable FAERS data shows case narratives involving: persistent nausea, transient visual disturbance, palpitations, injection-site granuloma, and one report of elevated liver enzymes (transaminase pattern, resolved on discontinuation)